Caris Life Sciences (CAI) Total Debt (2024 - 2026)

Caris Life Sciences' Total Debt history runs 3 years deep, the most recent figure standing at $381.2 million for Q1 2026.

• In Q1 2026, Total Debt changed N/A year-over-year to $381.2 million; the TTM figure through Mar 2026 stood at $381.2 million (changed N/A YoY), while the FY2025 annual figure was $379.0 million, down 12.52% from the prior year.
• Total Debt for Q1 2026 stood at $381.2 million, up from $379.0 million in the prior quarter.
• The five-year high for Total Debt was $433.2 million in Q4 2024, with the low at $373.5 million in Q2 2025.
• The 3-year median for Total Debt is $379.0 million (2025), against an average of $388.6 million.
• Peak annual rise in Total Debt reached 12.52% in 2025, while the deepest fall reached 12.52% in 2025.
• Caris Life Sciences' Total Debt stood at $433.2 million in 2024, then retreated by 12.52% to $379.0 million in 2025, then advanced by 0.59% to $381.2 million in 2026.
• Business Quant data shows CAI's Total Debt at $381.2 million in Q1 2026, $379.0 million in Q4 2025, and $376.0 million in Q3 2025.